Rubicon Technologies, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q3 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Rubicon Technologies, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q3 2021 to Q2 2024.
  • Rubicon Technologies, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $500K, a 54.5% decline year-over-year.
  • Rubicon Technologies, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $5.72M, a 94.6% decline year-over-year.
  • Rubicon Technologies, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $15M, a 85.1% decline from 2022.
  • Rubicon Technologies, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $101M, a 20097% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $5.72M $500K -$600K -54.5% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-21
Q1 2024 $6.32M $600K -$8.7M -93.5% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-20
Q4 2023 $15M $2.52M -$3.16M -55.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-28
Q3 2023 $18.2M $2.1M -$88.5M -97.7% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 $107M $1.1M -$1M -47.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-21
Q1 2023 $108M $9.3M +$6.7M +258% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-20
Q4 2022 $101M $5.69M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-28
Q3 2022 $90.6M +$89.8M +11225% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 $2.1M Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 $2.6M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-22
Q3 2021 $800K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-21
* An asterisk sign (*) next to the value indicates that the value is likely invalid.